Looking at Nordic American Tankers(NAT)

We took a great entry position, trading the 2027 $2.50 Strike calls in Nordic American Tankers (NAT).  Here is some information on NAT to support your due dilligencec

NAT is a prominent international tanker company specializing in the ownership and operation of Suezmax crude oil tankers. Here are key details about the company:

1. NAT was incorporated in Bermuda in 1995 and is headquartered in Hamilton, Bermuda.
2. The company operates a fleet of 20 Suezmax crude oil tankers, each capable of carrying up to 1 million barrels of oil.
3. NAT's business model focuses on simplicity, transparency, and predictability, ensuring a sustainable strategy in both strong and weak markets.
4. The company has been publicly listed on the New York Stock Exchange (NYSE) since September 1995 under the ticker symbol NAT.
5. NAT has a unique record of over 100 consecutive quarterly dividend declarations to shareholders. As of January 2025, it declared its 109th consecutive quarterly dividend of $0.04 per share, payable on January 16, 2025.
6. The company reported a net income of $8.7 million ($0.04 per share) for Q3 2024, up from $7.5 million in Q3 2023.
7. NAT secured time-charter contracts worth approximately $125 million with international and national oil companies in Q3 2024.
8. The company's fleet achieved an average time charter equivalent of $30,656 per day per ship, with daily operating costs around $9,000.
9. NAT emphasizes its non-participation in 'dark fleet' operations and avoidance of Suez Canal routes.

Gene Editing Focus is One Part of 2025's Strategy

This year we will continue to look towards gene editing companies to continue to provide outstanding returns.  NTLS puts have already proven successful this year.  Most of these companies are at 52-week lows currently but as with any biotech there are ups and downs based on interest and various catalysts.  Here are the companies and some basic research we are looking into and to help guide your own due diligence.  PUTS have been a great way to make recurring income but at some point, you may want to own one of these as they get close to successful commercialization.

1. Company Overview and Technology Platforms

CRISPR Therapeutics (NASDAQ: CRSP)

• Primary technology: CRISPR/Cas9 gene editing
• Key therapeutic areas:
  • Hemoglobinopathies (sickle cell disease, beta-thalassemia)
  • Immuno-oncology
  • Regenerative medicine
  • Type 1 diabetes

Intellia Therapeutics (NASDAQ: NTLA)

• Primary technology: CRISPR/Cas9 with proprietary delivery systems
• Focus areas:
  • In vivo gene editing (direct editing in body)
  • Ex vivo cell engineering
  • Transthyretin amyloidosis (ATTR)
  • Acute myeloid leukemia

Editas Medicine (NASDAQ: EDIT)

• Technology: CRISPR and TALENs
• Key programs:
  • Ocular diseases
  • Sickle cell disease
  • Cancer immunotherapy

Beam Therapeutics (NASDAQ: BEAM)

• Technology: Base editing (more precise CRISPR variant)
• Focus:
  • Hematologic diseases
  • Liver diseases
  • Cancer therapies

2. Clinical Trial Analysis Framework

Phase 1 Trials

• Safety assessment
• Dose-finding studies
• Initial efficacy signals
• Patient recruitment criteria
• Adverse events monitoring

Phase 2 Trials

• Efficacy evaluation
• Expanded patient populations
• Dosing optimization
• Biomarker analysis
• Safety continuation

Phase 3 Trials

• Large-scale efficacy confirmation
• Safety in broader populations
• Comparison with standard of care
• Long-term follow-up data
• Regulatory requirements

3. Key Clinical Programs to Monitor

CRISPR Therapeutics

• CTX001 (now exa-cel) for sickle cell disease and beta-thalassemia
  • Collaboration with Vertex Pharmaceuticals
  • Breakthrough therapy designation
  • Significant clinical success in early trials
  • Focus on long-term durability

Intellia Therapeutics

• NTLA-2001 for ATTR amyloidosis
  • First in vivo CRISPR therapy
  • Early clinical data showing protein reduction
  • Safety profile monitoring
  • Delivery system effectiveness

Editas Medicine

• EDIT-101 for LCA10 (eye disease)
  • First in vivo CRISPR treatment in humans
  • Safety and efficacy data collection
  • Dose escalation studies

4. Research Parameters to Track

Clinical Efficacy Metrics

• Disease-specific endpoints
• Biomarker changes
• Quality of life measurements
• Duration of therapeutic effect
• Treatment response rates

Safety Considerations

• Off-target editing effects
• Immune responses
• Long-term safety monitoring
• Adverse events classification
• Risk mitigation strategies

Technical Aspects

• Editing efficiency
• Delivery methods
• Target tissue specificity
• Manufacturing processes
• Scalability considerations

5. Competitive Analysis Framework

Market Position

• Patent portfolios
• Strategic partnerships
• Manufacturing capabilities
• Commercial readiness
• Market access strategies

Technical Differentiation

• Editing precision
• Delivery mechanisms
• Target selection
• Platform versatility
• Innovation pipeline

6. Future Research Directions

Emerging Technologies

• Next-generation editing tools
• Novel delivery systems
• Combination approaches
• Alternative gene modification methods
• Platform improvements

Therapeutic Expansion

• New disease targets
• Combination therapies
• Enhanced delivery methods
• Improved manufacturing
• Cost reduction strategies

IRobot (IRBT)

IRobot Up 25% on 8x volume.  Some technical trading going on with some short covering.  Not seeing the underlying cause other than that.  I'd take profits since we were recommending around 7 with 8 strikes for this month up strong!

I Sold Our Intelia Puts

 Some news was released about grants to employees which saw NTLA jump on good volume.  This has been a fairly volatile trade so I closed it out on the news this morning.  Since they were puts it is not the same scenario as my long call setup on RKLB.  If I held them I still had a max profit.  I took a 50% return on these.  Sell the news, buy the rumor sometimes works.  The JP Morgan conference is Friday which could prop NTLA up. We had 12.50 Puts so we did well.

"Rocket Lab & the Ghost of Losses Past: Why I Sabotaged My Own Success"

Trading is a relentless battle against our own minds. Logic and reason often take a backseat to fear, greed, and the haunting specter of past losses. This week, I fell victim to this psychological trap, and it cost me dearly.

I had a solid trade setup on Rocket Lab (RKLB). My research was thorough. My entry point was precise. My stop-loss was calculated. And most importantly, I had a clear exit strategy: hold until my target price was reached.

But then, the doubts crept in.

"What if this is another pump and dump?"

"What if I get greedy and hold too long, only to see it crash?"

These thoughts, fueled by past trading nightmares, began to erode my confidence. I remembered the agonizing losses, the sleepless nights, the self-recrimination that followed every ill-timed trade.

Instead of sticking to my plan, I succumbed to fear. I sold early, locking in a modest $8,500 profit.

The Aftermath

As I watched RKLB soar towards my target price, a wave of regret washed over me. My initial profit seemed insignificant compared to the $105,000 it was worth today, simply by trusting my plan.

This experience served as a harsh reminder that trading is as much about emotional management as it is about technical analysis. Past losses, while painful, should not dictate our future decisions.

Lessons Learned

• Trust Your Plan: Once you've conducted thorough research and developed a well-defined strategy, stick to it. Don't let fear or greed derail your execution.
• Embrace Discipline: Trading requires unwavering discipline. Emotional outbursts and impulsive decisions will inevitably lead to suboptimal results.
• Learn from Mistakes, Don't Dwell on Them: Past losses are inevitable. Analyze them objectively, learn valuable lessons, and move on.
• Focus on the Process, Not the Outcome: While profits are the ultimate goal, focus on executing your trades with precision and discipline. The results will follow.

This experience has been a costly but valuable lesson. I will strive to be more mindful of my emotions in future trades. I will learn to recognize and overcome the psychological obstacles that hinder my success.

I hope this blog post resonates with you. Have you ever sabotaged a successful trade due to psychological biases? Share your experiences in the comments below.

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice.